Compare
ALX Oncology Holdings Inc vs Rani Therapeutics Holdings, Inc. vs Spruce Biosciences, Inc. vs Werewolf Therapeutics, Inc.
| Latest fiscal year | ALX Oncology Holdings Inc ALXO | Rani Therapeutics Holdings, Inc. RANI | Spruce Biosciences, Inc. SPRB | Werewolf Therapeutics, Inc. HOWL |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $1.63M | $0 | n/a |
| Revenue growth (YoY) | n/a | +58.9% | -100.0% | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/m | n/a | n/a |
| Net margin | n/a | n/m | n/a | n/a |
| Net income | -$101.69M | -$40.95M | -$38.97M | -$60.82M |
| EPS (Diluted) | -$1.90 | -$0.45 | -$50.83 | -$1.33 |
| Operating cash flow | -$84.14M | -$18.71M | -$33.33M | -$60.29M |
| Free cash flow | -$84.35M | -$18.80M | n/a | -$60.29M |
| Cash & equivalents | $16.37M | $18.62M | $48.91M | $57.05M |
| Total assets | $59.05M | $58.62M | $53.02M | $69.40M |
| Total liabilities | $33.06M | $17.11M | $10.51M | $44.59M |
| Shareholders' equity | $25.98M | $33.01M | $42.52M | $24.80M |
| Return on year-end equity | -391.4% | -124.1% | -91.7% | -245.2% |
| Shares outstanding | 54.39M | n/a | 1.37M | 48.60M |
Revenue, most recent five fiscal years
| Fiscal year | ALX Oncology Holdings Inc | Rani Therapeutics Holdings, Inc. | Spruce Biosciences, Inc. | Werewolf Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $0 Ended 2022-12-31 | $1.63M Ended 2025-12-31 | $0 Ended 2025-12-31 | n/a |
| 1 year earlier | $0 Ended 2021-12-31 | $1.03M Ended 2024-12-31 | $4.91M Ended 2024-12-31 | n/a |
| 2 years earlier | $1.18M Ended 2020-12-31 | $0 Ended 2023-12-31 | $10.09M Ended 2023-12-31 | n/a |
| 3 years earlier | $4.80M Ended 2019-12-31 | $0 Ended 2022-12-31 | $0 Ended 2022-12-31 | n/a |
| 4 years earlier | $2.07M Ended 2018-12-31 | $2.72M Ended 2021-12-31 | n/a | n/a |